- Home
- TRVI vs ALF Comparison
TRVI vs ALF Comparison
Compare TRVI & ALF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- ALF
- Stock Information
- Founded
- TRVI 2011
- ALF 2024
- Country
- TRVI United States
- ALF United States
- Employees
- TRVI N/A
- ALF N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- ALF
- Sector
- TRVI Health Care
- ALF
- Exchange
- TRVI Nasdaq
- ALF NYSE
- Market Cap
- TRVI 363.7M
- ALF 363.3M
- IPO Year
- TRVI 2019
- ALF 2024
- Fundamental
- Price
- TRVI $4.60
- ALF $10.18
- Analyst Decision
- TRVI Strong Buy
- ALF
- Analyst Count
- TRVI 8
- ALF 0
- Target Price
- TRVI $9.31
- ALF N/A
- AVG Volume (30 Days)
- TRVI 739.7K
- ALF 12.5K
- Earning Date
- TRVI 03-19-2025
- ALF 01-01-0001
- Dividend Yield
- TRVI N/A
- ALF N/A
- EPS Growth
- TRVI N/A
- ALF N/A
- EPS
- TRVI N/A
- ALF N/A
- Revenue
- TRVI N/A
- ALF N/A
- Revenue This Year
- TRVI N/A
- ALF N/A
- Revenue Next Year
- TRVI N/A
- ALF N/A
- P/E Ratio
- TRVI N/A
- ALF N/A
- Revenue Growth
- TRVI N/A
- ALF N/A
- 52 Week Low
- TRVI $2.30
- ALF $9.96
- 52 Week High
- TRVI $5.05
- ALF $10.25
- Technical
- Relative Strength Index (RSI)
- TRVI 62.80
- ALF N/A
- Support Level
- TRVI $3.93
- ALF N/A
- Resistance Level
- TRVI $4.14
- ALF N/A
- Average True Range (ATR)
- TRVI 0.29
- ALF 0.00
- MACD
- TRVI 0.06
- ALF 0.00
- Stochastic Oscillator
- TRVI 64.82
- ALF 0.00
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.